# INVE Technologies, Inc.: financial statements, quarterly

INVE · Nasdaq · CIK 1036044 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inve.md) · [Financials](/companies/inve/financials.md) · [Filings](/companies/inve/filings.md) · [Insiders](/companies/inve/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inve/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.7](/filings/0000950170-24-125344.md) | [11.3 d](/filings/0000950170-25-040387.md) | [6.7](/filings/0000950170-25-068153.md) | [6.7](/filings/0000950170-25-106005.md) | [6.5](/filings/0001193125-25-274412.md) | [6.7 d](/filings/0001193125-26-126351.md) | [5.3](/filings/0001193125-26-223705.md) | [5.0](/filings/0001193125-26-349265.md) | [5.0](/filings/0001193125-25-274412.md) | [6.2 d](/filings/0001193125-26-126351.md) | [7.4](/filings/0001193125-26-223705.md) | [5.7](/filings/0001193125-26-349265.md) |
| Cost of revenue | $m | [10.4](/filings/0000950170-24-125344.md) | [9.5 d](/filings/0000950170-25-040387.md) | [6.2](/filings/0000950170-25-068153.md) | [6.1](/filings/0000950170-25-106005.md) | [6.3](/filings/0001193125-25-274412.md) | [7.7 d](/filings/0001193125-26-126351.md) | [5.1](/filings/0001193125-26-223705.md) | [5.5](/filings/0001193125-26-349265.md) | [4.5](/filings/0001193125-25-274412.md) | [5.1 d](/filings/0001193125-26-126351.md) | [6.1](/filings/0001193125-26-223705.md) | [4.8](/filings/0001193125-26-349265.md) |
| Gross profit | $m | [1.3](/filings/0000950170-24-125344.md) | [1.8 d](/filings/0000950170-25-040387.md) | [0.5](/filings/0000950170-25-068153.md) | [0.6](/filings/0000950170-25-106005.md) | [0.2](/filings/0001193125-25-274412.md) | [(1.0) d](/filings/0001193125-26-126351.md) | [0.1](/filings/0001193125-26-223705.md) | [(0.5)](/filings/0001193125-26-349265.md) | [0.5](/filings/0001193125-25-274412.md) | [1.1 d](/filings/0001193125-26-126351.md) | [1.3](/filings/0001193125-26-223705.md) | [0.9](/filings/0001193125-26-349265.md) |
| Research and development | $m | [1.0](/filings/0000950170-24-125344.md) | [1.2 d](/filings/0000950170-25-040387.md) | [0.9](/filings/0000950170-25-068153.md) | [1.0](/filings/0000950170-25-106005.md) | [1.1](/filings/0001193125-25-274412.md) | [0.9 d](/filings/0001193125-26-126351.md) | [0.8](/filings/0001193125-26-223705.md) | [0.9](/filings/0001193125-26-349265.md) | [0.8](/filings/0001193125-25-274412.md) | [0.8 d](/filings/0001193125-26-126351.md) | [1.0](/filings/0001193125-26-223705.md) | [1.0](/filings/0001193125-26-349265.md) |
| Operating income | $m | [(3.3)](/filings/0000950170-24-125344.md) | [(3.4) d](/filings/0000950170-25-040387.md) | [(5.1)](/filings/0000950170-25-068153.md) | [(6.7)](/filings/0000950170-25-106005.md) | [(9.6)](/filings/0001193125-25-274412.md) | [(6.6) d](/filings/0001193125-26-126351.md) | [(5.5)](/filings/0001193125-26-223705.md) | [(6.4)](/filings/0001193125-26-349265.md) | [(5.6)](/filings/0001193125-25-274412.md) | [(4.7) d](/filings/0001193125-26-126351.md) | [(4.2)](/filings/0001193125-26-223705.md) | [(5.5)](/filings/0001193125-26-349265.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125344.md) | [0.1 d](/filings/0000950170-25-040387.md) | [0.0](/filings/0000950170-25-068153.md) | [(0.0)](/filings/0000950170-25-106005.md) | [0.4](/filings/0001193125-25-274412.md) | [(0.3) d](/filings/0001193125-26-126351.md) | [0.0](/filings/0001193125-26-223705.md) | [0.1](/filings/0001193125-26-349265.md) | [(0.8)](/filings/0001193125-25-274412.md) | [0.5 d](/filings/0001193125-26-126351.md) | [0.0](/filings/0001193125-26-223705.md) | [0.0](/filings/0001193125-26-349265.md) |
| Net income | $m | [(0.0)](/filings/0000950170-24-125344.md) | [(1.6) d](/filings/0000950170-25-040387.md) | [(4.6)](/filings/0000950170-25-068153.md) | [(6.2)](/filings/0000950170-25-106005.md) | [85.9](/filings/0001193125-25-274412.md) | [(0.4) d](/filings/0001193125-26-126351.md) | [(4.8)](/filings/0001193125-26-223705.md) | [(6.0)](/filings/0001193125-26-349265.md) | [(3.5)](/filings/0001193125-25-274412.md) | [(3.7) d](/filings/0001193125-26-126351.md) | [(3.4)](/filings/0001193125-26-223705.md) | [(4.7)](/filings/0001193125-26-349265.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0000950170-24-125344.md) | not reported | [(0.21)](/filings/0000950170-25-068153.md) | [(0.27)](/filings/0000950170-25-106005.md) | [3.62](/filings/0001193125-25-274412.md) | not reported | [(0.21)](/filings/0001193125-26-223705.md) | [(0.26)](/filings/0001193125-26-349265.md) | [(0.15)](/filings/0001193125-25-274412.md) | not reported | [(0.15)](/filings/0001193125-26-223705.md) | [(0.20)](/filings/0001193125-26-349265.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0000950170-24-125344.md) | not reported | [(0.21)](/filings/0000950170-25-068153.md) | [(0.27)](/filings/0000950170-25-106005.md) | [3.62](/filings/0001193125-25-274412.md) | not reported | [(0.21)](/filings/0001193125-26-223705.md) | [(0.26)](/filings/0001193125-26-349265.md) | [(0.15)](/filings/0001193125-25-274412.md) | not reported | [(0.15)](/filings/0001193125-26-223705.md) | [(0.20)](/filings/0001193125-26-349265.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.7](/filings/0000950170-23-061217.md) | [23.3](/filings/0000950170-25-040387.md) | [21.6](/filings/0000950170-24-057322.md) | [18.4](/filings/0000950170-24-094283.md) | [145](/filings/0000950170-24-125344.md) | [136](/filings/0001193125-26-126351.md) | [132](/filings/0000950170-25-068153.md) | [129](/filings/0000950170-25-106005.md) | [126](/filings/0001193125-25-274412.md) | [129](/filings/0001193125-26-349265.md) | [125](/filings/0001193125-26-223705.md) | [119](/filings/0001193125-26-349265.md) |
| Current assets | $m | [81.5](/filings/0000950170-23-061217.md) | [79.5](/filings/0000950170-25-040387.md) | [72.9](/filings/0000950170-24-057322.md) | [69.4](/filings/0000950170-24-094283.md) | [166](/filings/0000950170-24-125344.md) | [153](/filings/0001193125-26-126351.md) | [149](/filings/0000950170-25-068153.md) | [144](/filings/0000950170-25-106005.md) | [142](/filings/0001193125-25-274412.md) | [143](/filings/0001193125-26-349265.md) | [139](/filings/0001193125-26-223705.md) | [132](/filings/0001193125-26-349265.md) |
| Total assets | $m | [111](/filings/0000950170-23-061217.md) | [110](/filings/0000950170-25-040387.md) | [102](/filings/0000950170-24-057322.md) | [97.8](/filings/0000950170-24-094283.md) | [177](/filings/0000950170-24-125344.md) | [163](/filings/0001193125-26-126351.md) | [159](/filings/0000950170-25-068153.md) | [154](/filings/0000950170-25-106005.md) | [151](/filings/0001193125-25-274412.md) | [151](/filings/0001193125-26-349265.md) | [148](/filings/0001193125-26-223705.md) | [141](/filings/0001193125-26-349265.md) |
| Current liabilities | $m | [31.7](/filings/0000950170-23-061217.md) | [30.8](/filings/0000950170-25-040387.md) | [27.3](/filings/0000950170-24-057322.md) | [28.2](/filings/0000950170-24-094283.md) | [19.0](/filings/0000950170-24-125344.md) | [8.0](/filings/0001193125-26-126351.md) | [7.3](/filings/0000950170-25-068153.md) | [6.6](/filings/0000950170-25-106005.md) | [6.7](/filings/0001193125-25-274412.md) | [9.4](/filings/0001193125-26-349265.md) | [9.3](/filings/0001193125-26-223705.md) | [6.5](/filings/0001193125-26-349265.md) |
| Total liabilities | $m | [36.6](/filings/0000950170-23-061217.md) | [35.5](/filings/0000950170-25-040387.md) | [31.6](/filings/0000950170-24-057322.md) | [32.7](/filings/0000950170-24-094283.md) | [20.3](/filings/0000950170-24-125344.md) | [9.2](/filings/0001193125-26-126351.md) | [8.2](/filings/0000950170-25-068153.md) | [7.5](/filings/0000950170-25-106005.md) | [7.4](/filings/0001193125-25-274412.md) | [10.6](/filings/0001193125-26-349265.md) | [10.5](/filings/0001193125-26-223705.md) | [7.6](/filings/0001193125-26-349265.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [9.9](/filings/0000950170-23-061217.md) | [9.9](/filings/0000950170-25-040387.md) | [9.9](/filings/0000950170-24-057322.md) | [7.9](/filings/0000950170-24-094283.md) | [0.0](/filings/0000950170-24-125344.md) | [0.0](/filings/0000950170-25-040387.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [74.8](/filings/0000950170-24-125344.md) | [74.3](/filings/0001193125-26-126351.md) | [70.2](/filings/0000950170-25-106005.md) | [65.1](/filings/0001193125-25-274412.md) | [157](/filings/0001193125-25-274412.md) | [154](/filings/0001193125-26-349265.md) | [150](/filings/0001193125-26-349265.md) | [146](/filings/0001193125-26-349265.md) | [144](/filings/0001193125-25-274412.md) | [141](/filings/0001193125-26-349265.md) | [137](/filings/0001193125-26-349265.md) | [133](/filings/0001193125-26-349265.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(322) d](/filings/0000950170-24-125344.md) | [4,771 d](/filings/0000950170-25-040387.md) | [(1,301)](/filings/0000950170-25-068153.md) | [(993) d](/filings/0000950170-25-106005.md) | [(7,216) d](/filings/0001193125-25-274412.md) | [(5,923) d](/filings/0001193125-26-126351.md) | [(3,280)](/filings/0001193125-26-223705.md) | [(3,568) d](/filings/0001193125-26-349265.md) | [(2,881) d](/filings/0001193125-25-274412.md) | [3,026 d](/filings/0001193125-26-126351.md) | [(2,835)](/filings/0001193125-26-223705.md) | [(4,360) d](/filings/0001193125-26-349265.md) |
| Capital expenditure | $k | [711 d](/filings/0000950170-24-125344.md) | [1,145 d](/filings/0000950170-25-040387.md) | [232](/filings/0000950170-25-068153.md) | [135 d](/filings/0000950170-25-106005.md) | [506 d](/filings/0001193125-25-274412.md) | [620 d](/filings/0001193125-26-126351.md) | [301](/filings/0001193125-26-223705.md) | [252 d](/filings/0001193125-26-349265.md) | [352 d](/filings/0001193125-25-274412.md) | [203 d](/filings/0001193125-26-126351.md) | [882](/filings/0001193125-26-223705.md) | [707 d](/filings/0001193125-26-349265.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.3](/filings/0000950170-23-061217.md) | [22.8](/filings/0000950170-24-057322.md) | [23.1](/filings/0000950170-24-094283.md) | [23.2](/filings/0000950170-24-125344.md) | [23.4](/filings/0000950170-25-068153.md) | [23.5](/filings/0000950170-25-106005.md) | [23.7](/filings/0001193125-25-274412.md) | [23.6](/filings/0001193125-26-223705.md) | [23.8](/filings/0001193125-26-349265.md) | [23.8](/filings/0001193125-25-274412.md) | [24.0](/filings/0001193125-26-223705.md) | [24.2](/filings/0001193125-26-349265.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,235,753 at 2026-08-04, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349265.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.